Mortality did not decrease, compared with placebo, in patients with chronic obstructive pulmonary disease (COPD) and cardiovascular disease risk who took the inhaled corticosteroid fluticasone furoate ...

Please provide your email address to receive an email when new articles are posted on . Patients with chronic obstructive pulmonary disease treated with a combination of fluticasone furoate and ...

In a recent article published in the New England Journal of Medicine, researchers presented the findings of an ongoing double-blinded, randomized, placebo-controlled platform-protocol clinical trial, ...

LONDON, UNITED KINGDOM and SOUTH SAN FRANCISCO, CA--(Marketwired - Apr 22, 2014) - GlaxoSmithKline (LSE: GSK) (NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced the start of a Phase III ...

DUBLIN--(BUSINESS WIRE)--The "Fluticasone Furoate / Vilanterol Sales, Price Analysis, & Sales Forecast - 2017" report has been added to Research and Markets' offering. Discover the growth trends of ...

HealthDay News — A combination of fluticasone furoate and vilanterol reduces the rate of moderate or severe exacerbations among patients with chronic obstructive pulmonary disease (COPD), according to ...

Fluticasone furoate/vilanterol (FF/VI) improved FEV1 but did not improve morning peak expiratory flow in pediatric patients with uncontrolled asthma. Among pediatric patients with uncontrolled asthma, ...

To assess the safety and efficacy of fluticasone furoate nasal spray (FFNS) compared with placebo for symptomatic relief of uncomplicated ARS. A statistically significant reduction was seen in the ...

Patients who received fluticasone furoate-vilanterol had a 9% lower risk for a first moderate or severe COPD exacerbation than those who received budesonide-formoterol (hazard ratio [HR], 0.91; 95% CI ...

Trelegy Ellipta combines fluticasone furoate, an inhaled corticosteroid with umeclidinium, an anticholinergic and vilanterol, a long-acting β2-adrenergic agonist. The Food and Drug Administration (FDA ...

Which therapy more effectively reduces severe COPD exacerbations: once-daily FF/UMEC/VI or twice-daily ICS/LABA? Treatment with once-daily single-inhaler fluticasone ...

DUBLIN--(BUSINESS WIRE)--The "Drug Overview: Trelegy Ellipta" report has been added to ResearchAndMarkets.com's offering. Trelegy Ellipta ([fluticasone furoate + vilanterol + umeclidinium bromide]; ...